O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	20	25	study
O	26	28	of
O	29	35	weekly
B-intervention	36	46	paclitaxel
I-intervention	47	51	with
I-intervention	52	55	and
I-intervention	56	63	without
I-intervention	64	75	carboplatin
I-intervention	76	84	followed
I-intervention	85	87	by
I-intervention	88	104	cyclophosphamide
I-intervention	104	105	/
I-intervention	105	115	epirubicin
I-intervention	115	116	/
I-intervention	116	117	5
I-intervention	117	118	-
I-intervention	118	130	fluorouracil
O	131	133	as
O	134	145	neoadjuvant
O	146	158	chemotherapy
O	159	162	for
O	163	168	stage
O	169	171	II
O	171	172	/
O	172	176	IIIA
O	177	183	breast
O	184	190	cancer
O	191	198	without
O	199	203	HER2
O	204	218	overexpression
O	218	219	.

O	220	228	Addition
O	229	231	of
O	232	243	carboplatin
O	244	246	to
O	247	258	neoadjuvant
O	259	271	chemotherapy
O	272	274	in
O	275	279	HER2
O	279	280	-
O	280	288	negative
O	289	295	breast
O	296	302	cancer
O	303	306	may
O	307	314	improve
O	315	327	pathological
O	328	336	complete
O	337	345	response
O	346	347	(
O	347	350	pCR
O	350	351	)
O	352	357	rates
O	357	358	.

O	359	361	We
O	362	371	evaluated
O	372	375	the
O	376	384	efficacy
O	385	388	and
O	389	395	safety
O	396	398	of
O	399	410	carboplatin
O	411	414	and
O	415	421	weekly
O	422	432	paclitaxel
O	433	434	(
O	434	438	wPTX
O	438	439	)
O	440	448	followed
O	449	451	by
O	452	468	cyclophosphamide
O	468	469	,
O	470	480	epirubicin
O	480	481	,
O	482	485	and
O	486	487	5
O	487	488	-
O	488	500	fluorouracil
O	501	502	(
O	502	505	CEF
O	505	506	)
O	507	509	as
O	510	521	neoadjuvant
O	522	534	chemotherapy
O	535	538	for
O	539	543	HER2
O	543	544	-
O	544	552	negative
O	553	559	breast
O	560	566	cancer
O	566	567	.

B-eligibility	568	576	Patients
I-eligibility	577	581	with
I-eligibility	582	587	stage
I-eligibility	588	590	II
I-eligibility	590	591	/
I-eligibility	591	595	IIIA
I-eligibility	596	600	HER2
I-eligibility	600	601	-
I-eligibility	601	609	negative
I-eligibility	610	616	breast
I-eligibility	617	623	cancer
O	624	628	were
O	629	637	randomly
O	638	646	assigned
O	647	649	to
O	650	664	preoperatively
O	665	672	receive
O	673	675	CP
O	675	676	-
O	676	679	CEF
O	680	681	(
O	681	685	four
O	686	687	3
O	687	688	-
O	688	692	week
O	693	699	cycles
O	700	702	of
O	703	714	carboplatin
O	715	716	[
O	716	720	area
O	721	726	under
O	727	730	the
O	731	736	curve
O	737	738	5
O	739	741	mg
O	741	742	/
O	742	744	mL
O	744	745	/
O	745	748	min
O	748	749	,
O	750	753	day
O	754	755	1
O	755	756	]
O	757	760	and
O	761	765	wPTX
O	766	767	[
O	767	769	80
O	770	772	mg
O	772	773	/
O	773	774	m
O	774	775	(
O	775	776	2
O	776	777	)
O	777	778	,
O	779	782	day
O	783	784	1
O	784	785	,
O	786	787	8
O	787	788	,
O	789	791	15
O	791	792	]
O	793	801	followed
O	802	804	by
O	805	809	four
O	810	811	3
O	811	812	-
O	812	816	week
O	817	823	cycles
O	824	826	of
O	827	830	CEF
O	831	832	[
O	832	835	500
O	835	836	/
O	836	839	100
O	839	840	/
O	840	843	500
O	844	846	mg
O	846	847	/
O	847	848	m
O	848	849	(
O	849	850	2
O	850	851	)
O	851	852	]
O	853	855	or
B-control	856	857	P
I-control	857	858	-
I-control	858	861	CEF
O	862	863	(
O	863	867	four
O	868	874	cycles
O	875	877	of
O	878	882	wPTX
O	883	891	followed
O	892	894	by
O	895	899	four
O	900	906	cycles
O	907	909	of
O	910	913	CEF
O	913	914	)
O	914	915	.

O	916	919	The
O	920	927	primary
O	928	937	objective
O	938	941	was
B-outcome-Measure	942	945	pCR
I-outcome-Measure	946	950	rate
O	950	951	.

O	952	954	Of
B-total-participants	955	958	181
O	959	967	eligible
O	968	976	patients
O	976	977	,
B-intervention-participants	978	980	89
O	981	985	were
O	986	994	randomly
O	995	1003	assigned
O	1004	1006	to
O	1007	1010	the
O	1011	1013	CP
O	1013	1014	-
O	1014	1017	CEF
O	1018	1021	and
B-control-participants	1022	1024	92
O	1025	1027	to
O	1028	1031	the
O	1032	1033	P
O	1033	1034	-
O	1034	1037	CEF
O	1037	1038	.

O	1039	1042	Two
O	1043	1051	patients
O	1052	1054	in
O	1055	1059	each
O	1060	1063	arm
O	1064	1071	refused
O	1072	1074	to
O	1075	1082	receive
O	1083	1094	neoadjuvant
O	1095	1107	chemotherapy
O	1107	1108	.

O	1109	1116	Overall
B-intervention-participants	1117	1119	88
O	1120	1128	patients
O	1129	1131	in
O	1132	1135	the
O	1136	1138	CP
O	1138	1139	-
O	1139	1142	CEF
O	1143	1146	and
B-control-participants	1147	1149	91
O	1150	1158	patients
O	1159	1161	in
O	1162	1165	the
O	1166	1167	P
O	1167	1168	-
O	1168	1171	CEF
O	1172	1176	were
O	1177	1187	assessable
O	1188	1191	for
O	1192	1200	efficacy
O	1201	1204	and
O	1205	1211	safety
O	1211	1212	.

O	1213	1216	The
B-outcome	1217	1220	pCR
I-outcome	1221	1225	rate
O	1226	1228	in
O	1229	1232	the
O	1233	1235	CP
O	1235	1236	-
O	1236	1239	CEF
O	1240	1243	was
O	1244	1257	significantly
O	1258	1264	higher
O	1265	1269	than
O	1270	1274	that
O	1275	1277	in
O	1278	1281	the
O	1282	1283	P
O	1283	1284	-
O	1284	1287	CEF
O	1288	1289	(
B-iv-bin-percent	1289	1291	31
I-iv-bin-percent	1291	1292	.
I-iv-bin-percent	1292	1293	8
O	1294	1296	vs
O	1296	1297	.
B-cv-bin-percent	1298	1300	17
I-cv-bin-percent	1300	1301	.
I-cv-bin-percent	1301	1302	6
I-cv-bin-percent	1303	1304	%
O	1304	1305	,
O	1306	1309	one
O	1309	1310	-
O	1310	1315	sided
O	1316	1317	P
O	1318	1319	=
O	1320	1321	0
O	1321	1322	.
O	1322	1324	01
O	1324	1325	)
O	1325	1326	.

O	1327	1332	Among
O	1333	1341	patients
O	1342	1346	with
O	1347	1353	triple
O	1353	1354	-
O	1354	1362	negative
O	1363	1369	breast
O	1370	1376	cancer
O	1376	1377	,
O	1378	1381	the
B-outcome	1382	1385	pCR
I-outcome	1386	1390	rate
O	1391	1393	in
O	1394	1397	the
O	1398	1400	CP
O	1400	1401	-
O	1401	1404	CEF
O	1405	1408	was
O	1409	1422	significantly
O	1423	1429	higher
O	1430	1434	than
O	1435	1439	that
O	1440	1442	in
O	1443	1446	the
O	1447	1448	P
O	1448	1449	-
O	1449	1452	CEF
O	1453	1454	[
B-iv-bin-percent	1454	1456	61
I-iv-bin-percent	1456	1457	.
I-iv-bin-percent	1457	1458	2
O	1459	1460	(
B-iv-bin-abs	1460	1462	23
O	1462	1463	/
B-intervention-participants	1463	1465	37
O	1465	1466	)
O	1467	1469	vs
O	1469	1470	.
B-cv-bin-percent	1471	1473	26
I-cv-bin-percent	1473	1474	.
I-cv-bin-percent	1474	1475	3
I-cv-bin-percent	1476	1477	%
O	1478	1479	(
B-cv-bin-abs	1479	1481	10
O	1481	1482	/
B-control-participants	1482	1484	38
O	1484	1485	)
O	1485	1486	,
O	1487	1488	P
O	1489	1490	=
O	1491	1492	0
O	1492	1493	.
O	1493	1496	003
O	1496	1497	]
O	1497	1498	.

B-outcome	1499	1504	Grade
I-outcome	1505	1506	3
I-outcome	1506	1507	-
I-outcome	1507	1508	4
I-outcome	1509	1520	neutropenia
O	1521	1524	was
O	1525	1533	observed
O	1534	1536	in
O	1537	1540	the
O	1541	1543	CP
O	1543	1544	-
O	1544	1547	CEF
O	1548	1552	more
O	1553	1563	frequently
O	1564	1568	than
O	1569	1571	in
O	1572	1575	the
O	1576	1577	P
O	1577	1578	-
O	1578	1581	CEF
O	1582	1583	(
B-iv-bin-percent	1583	1585	65
I-iv-bin-percent	1585	1586	.
I-iv-bin-percent	1586	1587	9
O	1588	1590	vs
O	1590	1591	.
B-cv-bin-percent	1592	1594	38
I-cv-bin-percent	1594	1595	.
I-cv-bin-percent	1595	1596	5
I-cv-bin-percent	1597	1598	%
O	1598	1599	)
O	1599	1600	.

O	1601	1607	Adding
O	1608	1619	carboplatin
O	1620	1622	to
O	1623	1634	neoadjuvant
O	1635	1639	wPTX
O	1640	1648	followed
O	1649	1651	by
O	1652	1655	CEF
O	1656	1659	for
O	1660	1664	HER2
O	1664	1665	-
O	1665	1673	negative
O	1674	1680	breast
O	1681	1687	cancer
O	1688	1696	improved
O	1697	1700	the
O	1701	1704	pCR
O	1705	1709	rate
O	1710	1713	and
O	1714	1725	exacerbated
O	1726	1740	hematotoxicity
O	1740	1741	.
